The bromodomain and extra-terminal (BET) bromodomains, particularly BRD4, have been identified as promising therapeutic targets in the treatment of many human disorders such as cancer, inflammation, obesity, and cardiovascular disease. This evidence concerns the gene BRD4 and obesity due to melanocortin 4 receptor deficiency.